Owner's Guides

Pharmacies for Sale: Selling and Valuing an Independent Pharmacy

How independent pharmacy sales and valuations actually work in the US: SDE multiples, buyer types, PBM risk, licensing, and the real timeline.

Palmstone Capital Research12 min read

The script file is the asset.

If you own an independent pharmacy and you're weighing pharmacy businesses for sale against staying open another five years, the numbers you need aren't the ones most brokers lead with. Independent pharmacies did $103 billion in sales in 2024 across 18,960 locations, and average store revenue climbed to $5.411 million. That looks like a growth story until you check gross profit: it fell to 18.2%, a ten-year low, because GLP-1 volume and thin reimbursement inflate the top line without adding cash flow. Pharmacy valuations have to separate the two, or a seller ends up chasing a multiple that was never really there.

Your decision: retire, sell to staff, or sell to a chain

Most owners arrive here from one of three directions, and the path changes what "for sale" should mean.

Retiring with no successor in the family. This is the most common route, and it points toward a marketed sale to a local pharmacist, a regional independent group, or occasionally a chain. NCPA and PRS Pharmacy Services both source buyers in this category, and it's the group most likely to keep the store, staff, and brand intact. SBA financing is common on their side, which affects how patient you can be on price versus certainty of close.

Selling to an employee or associate pharmacist. An internal buyer already knows the payer mix, the PIC responsibilities, and the patients. It's slower to arrange because the buyer usually needs financing help, sometimes a seller note, but it protects continuity and reduces the diligence surprises that kill deals with outside buyers.

Exiting fast, or exiting a store that's already struggling. If the pharmacy is distressed, closed, or running negative cash flow, going-concern value often disappears. What's left is asset value plus usable inventory, and sometimes a prescription-file sale to a nearby chain location. This path prices closer to 1.7x SDE or lower, and it's a different negotiation entirely from a healthy sale.

None of these require the same buyer conversation, so decide which lane you're in before you talk multiples.

What your pharmacy is actually worth

Pharmacy valuations lean on seller's discretionary earnings (SDE), which is EBITDA plus the owner's compensation, benefits, and defensible discretionary add-backs. That's the right basis for an owner-operated single store. Once the store runs without you, buyers shift to adjusted EBITDA, which charges a market-rate replacement pharmacist against earnings before anything gets added back. Revenue is a cross-check only, because a $5 million pharmacy full of low-margin GLP-1 fills can be worth less than a $2 million pharmacy with clean gross profit per prescription.

The best available closed-sale evidence comes from BizBuySell's pharmacy transaction data, 2021 through 2025:

Metric	Lower quartile	Median	Average	Upper quartile
Sale price / SDE	1.69x	2.45x	2.79x	3.75x
Sale price / revenue	0.20x	0.29x	0.42x	0.45x
Asking price / SDE	2.35x	3.02x	4.96x	4.32x

Note the gap between asking and closed multiples. Sellers list at 3.02x median; the market clears at 2.45x. In 2025 specifically, sold pharmacies averaged 2.95x SDE and 0.45x revenue, with a $600,000 median sale price and a 97% sale-to-ask ratio, both stronger than 2024's $382,500 median and 91% ratio. BizBuySell also notes that pharmacies above $2 million in revenue tend to sell above 3x earnings, while stores under $500,000 in revenue often land near 1.7x or lower. This is a national, self-reported dataset of mostly small businesses, not a full transaction census, so treat it as directional rather than a price tag.

Larger or specialized pharmacies price differently. Long-term care pharmacies have traded in the 5.0x-7.0x adjusted EBITDA range in recent deals; compounding pharmacies with 503A or 503B status and sterile capability have reached 6.0x-8.5x. Both figures rest on a thin set of disclosed transactions and should be treated as estimates, not benchmarks you can bank on without a specific comparable.

A worked example

Take a community pharmacy with $2.4 million in revenue and SDE of $220,000 after normalizing owner compensation, one-time COVID-era income, and related-party rent. At the reported 2025 median of 2.45x SDE, going-concern goodwill would be about $539,000. Add verified saleable inventory, priced at landed cost after excluding expired and short-dated stock, say $180,000. That puts a rough enterprise value near $719,000 before real estate, debt payoff, and closing adjustments. If the store instead sits at the upper end of the range because of clean payer mix and low owner dependence, 3.5x SDE would put goodwill near $770,000 before inventory. The spread between those two numbers is the entire argument for spending time on earnings normalization before you list.

What actually moves the number

Buyers pay for gross profit growth, not revenue growth. A pharmacy with rising sales but flat or falling gross profit per prescription, driven by high-cost GLP-1 fills or negative-reimbursement drugs, gets discounted hard regardless of the top line. Diversified payer and prescriber bases help; a store where one facility, one prescriber, or one 340B covered entity drives most of the profit gets treated as high-risk, because that relationship can walk on day one of new ownership.

Open PBM audits or extrapolated recoupments are a common deal-killer. So is a short lease with no landlord consent path, or a controlled-substance discrepancy that surfaces in DEA inventory reconciliation. On the upside, a transferable lease with renewal options, a pharmacist-in-charge willing to stay through transition, and clean board, DEA, and OIG history all support the higher end of any range.

Remember that Medicare Part D and Medicaid together represented 52% of independent-pharmacy prescriptions in 2024. That's not a red flag by itself, but a buyer will test net reimbursement on those claims specifically rather than assuming every script carries equal profit.

Who's actually buying

Local pharmacists and regional independent groups are the most common buyer for a healthy going-concern store, and the group most likely to preserve the store and staff. They're sourced through NCPA and PRS Pharmacy Services, and this buyer type maps most directly to the 1.7x-3.75x SDE sold range.

National chains buy prescription files and select stores where a nearby location can absorb the patients. CVS Pharmacy completed acquisitions of assets from 63 former Rite Aid and Bartell stores plus prescription files from 626 pharmacies across 15 states in 2025. Walgreens, Kroger, Albertsons, and Giant Eagle also picked up assets out of the Rite Aid bankruptcy. These deals usually don't assume your lease, employees, or liabilities, and the price is rarely disclosed.

Long-term care consolidators including Guardian Pharmacy Services, Clarest Health, and BrightSpring/PharMerica buy for facility contracts and resident census. Guardian alone closed two acquisitions in 2025, Mercury Pharmacy Services in June and North Ridge Pharmacy late in the year, ending the year with 54 full-service pharmacies.

Compounding and specialty platforms such as Revelation Pharma (backed by Osceola Capital) and Wedgewood Pharmacy (majority-owned by Partners Group) are active acquirers of 503A and 503B assets with sterile capability and multistate licensing.

Separately, Sycamore Partners completed its $23.7 billion take-private of Walgreens in August 2025. That's a market-structure signal, not a comparable for a single independent store, but it tells you where institutional capital is pointed in this sector.

Prescription files versus selling the whole store

A file-only sale to a chain looks simpler on paper: no lease assumption, no staff transition, sometimes a fast close. Some advisers cite 15%-25% of annual prescription revenue as a rough rule of thumb for file value, but treat that as a loose estimate, not cash-flow analysis. At current drug costs, that percentage can badly overvalue low-margin scripts. A more grounded estimate lands around $5-$15 per historical annual prescription, adjusted for expected retention and profit quality, though actual chain purchase prices are almost always private.

The real comparison is net proceeds, not headline number. A file sale commonly leaves you holding the lease, front-end inventory, employee liabilities, receivables, and wind-down costs. A going-concern buyer is more likely to assume the lease and staff, which changes your closing costs even if the sticker price is lower. And patient choice is real: a database transfer doesn't guarantee patients follow the buyer.

Inventory and what happens at closing

Inventory is normally counted immediately before closing and priced at verified landed cost, or lower of cost and realizable value. Expired, short-dated, opened, recalled, and nonreturnable stock is excluded, and controlled substances require separate DEA and state inventories on the transfer date, with Schedule II items moving under DEA Form 222 or compliant electronic ordering.

There's no universal convention on whether inventory is included in your quoted multiple. Some deals price goodwill from SDE and add inventory separately at cost; others fold it in. State this explicitly in your LOI, or you and the buyer will both assume the other side covered it.

Wholesale rebates and chargebacks need explicit allocation for the same reason. Real estate, if you own the building, should be valued separately at appraisal or market rent, not folded into the SDE multiple with the building's occupancy cost still sitting inside earnings.

Licenses, DEA, and payer contracts don't just transfer

This is where pharmacy sales differ most from a typical small-business sale, and where deals stall if you start too late.

State pharmacy permit. An asset sale or new legal entity generally requires a new facility permit from the state board of pharmacy, a PIC designation, ownership disclosure, and inspection before you can dispense. Rules vary by state; a few, like North Dakota, generally require majority pharmacist ownership.

DEA registration. This is not freely assignable. A seller ending controlled-substance activity must notify the DEA Special Agent in Charge at least 14 days before the proposed transfer, absent a waiver, under 21 CFR 1301.52. Final and opening inventories are taken on the transfer date, and pre-close discrepancies remain seller exposure.

NCPDP/NABP identifiers. Ownership changes must be reported, and NABP requires notice within 30 days after the final change. Accreditation is not assignable without written approval.

PBM contracts. CVS Caremark's 2026 Provider Manual, for example, may require a buyer without an existing relationship to sign a new provider agreement and complete credentialing. Assignment is discretionary, and change of ownership isn't effective until the PBM issues a written decision.

Medicaid and DMEPOS. New entity or ownership changes trigger separate state Medicaid re-enrollment, and a change in TIN can require a new CMS-855S for DMEPOS. As of mid-2026, CMS has a temporary nationwide moratorium on new DMEPOS supplier enrollments for certain categories, so confirm whether your buyer's structure is caught before you price that revenue line.

Build a credentialing timeline that runs in parallel with diligence, not after closing. Losing PBM network eligibility for even a few weeks after a change of ownership can gut working capital.

Financing: how buyers pay for it

SBA 7(a) is the dominant financing tool for independent-pharmacy acquisitions. For loans above $350,000, the program allows up to $5 million with a 75% guaranty, commonly a 10-year term against goodwill and business assets, and a typical minimum 10% buyer injection. As of mid-2026, the variable-rate ceiling on those loans is Prime plus 3.0%, roughly 9.75%. A combined 7(a)/504 structure, available since July 2026, lets an eligible borrower stack up to $5 million of each for as much as $10 million total, though the 504 portion is restricted to eligible fixed assets like owner-occupied real estate, not goodwill or inventory.

Specialty pharmacy lenders exist outside SBA. Live Oak Bank's Express product covers $10,000-$350,000 for inventory, script purchases, and working capital at roughly 10%-13%. Affiniti/Emigrant Bank offers pharmacy-specific lines and term loans at roughly 10%-15% APR. Note that SBA policy applied from March 2026 requires all owners and required guarantors to be U.S. citizens or nationals, a rule under active legal-process scrutiny as of a July 2026 GAO decision, so confirm current eligibility before relying on it in a deal timeline.

Whatever the source, debt service is the real ceiling on price. If your normalized SDE can't service the buyer's likely SBA payment after replacement pharmacist cost, taxes, and working capital, an agreed price on paper won't survive underwriting.

The tax question: asset sale or stock sale

Most independent pharmacy deals are structured as asset sales. Inventory gain is taxed as ordinary income to you as seller, while goodwill and going-concern value may qualify for capital-gain treatment. The buyer gets a stepped-up basis, and both sides typically file IRS Form 8594 to report the purchase-price allocation under the residual method. Buyers generally push for that allocation to favor faster-depreciating assets and inventory; sellers push toward goodwill.

Stock or membership-interest sales let a seller claim straight capital-gain treatment, which is often more attractive, but the buyer inherits the entity's historic liabilities and typically gets no basis step-up. If you're a C corporation, an asset sale can trigger tax at the corporate level and again on distribution to shareholders, a real reason C-corp sellers often push for stock treatment or a higher price to compensate.

Timeline

A marketed, financed going-concern sale runs roughly 6-10 months from readiness work to closing. A clean strategic or cash deal can move faster; a chain buying prescription files only has closed in as little as three months in some cases. What extends the timeline almost every time is licensing and credentialing, not negotiation.

Stage	Typical duration
Readiness and valuation	2-4 weeks
Confidential materials and buyer list	1-2 weeks
Buyer outreach and indications	4-10 weeks
LOI and exclusivity	1-3 weeks
Confirmatory diligence and financing	6-10 weeks
Licensure, accreditation, payer credentialing	8-16 weeks, run in parallel
Definitive documents and closing	3-6 weeks, overlaps diligence
Transition and true-ups	2-12 weeks after close

Start the state permit, DEA, NCPDP, and PBM credentialing work immediately after signing the LOI, wherever disclosure rules allow. Waiting until after closing to start that process is the single most common reason a pharmacy sale drags past ten months.

The mistakes that cost sellers real money

Sellers who lead with revenue instead of gross profit consistently overprice themselves and then wonder why offers come in low. Sellers who call SDE "EBITDA" without deducting a replacement pharmacist cost hand buyers a reason to renegotiate mid-diligence. And sellers who assume their DEA number, NCPDP number, and PBM contracts simply carry over to the new owner discover otherwise, usually at the worst possible moment in the timeline. Get your earnings normalized, your license and contract picture mapped, and your inventory records clean before you go to market, not during it.

FAQ

How much is my pharmacy worth?

For reported owner-operated U.S. sales, the middle 50% ran 1.69x-3.75x SDE with a 2.45x median in the 2021-2025 dataset. Inventory treatment, real estate, debt, payer quality, and whether the store stays open all change what actually lands in your pocket.

Is inventory included in the multiple?

There's no universal convention. Many small deals price goodwill from SDE and add verified saleable inventory at cost on top. Your LOI needs to state this explicitly so neither side double-counts or under-counts it.

Should I take a prescription-file offer or sell the operating store?

Compare net proceeds, not the headline number. A file sale often leaves you with the lease, front-end inventory, staff liabilities, and wind-down costs. A going-concern sale is more likely to have the buyer assume those, even at a lower quoted price.

Do my DEA number, NCPDP number, and PBM contracts transfer automatically?

No. DEA registration is not freely assignable, NCPDP requires ownership reporting, and PBMs like CVS Caremark may require a new provider agreement and full credentialing. Plan for this from the day you sign the LOI.

How long does a pharmacy sale take?

A marketed, financed going-concern sale usually takes 6-10 months. Chain file-only purchases can close faster. State licensing, PBM credentialing, and SBA underwriting are the most common reasons a timeline stretches past that.